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Background. Allergen-speciﬁc immunotherapy (SIT) is one of the important regimens for the treatment of allergic diseases.
Predictive tests for the clinical response to SIT are limited. In this study we aimed to evaluate whether speciﬁc IgE/total IgE
levels can predict clinical improvement in monosensitized patients to house dust mite treated with immunotherapy. Patients and
Methods. We analyzed 32 patients who had undergone 2 years of SIT. Serum t-IgE and s-IgE levels, and serum s-IgE/t-IgE ratios
were calculated and tested for correlation with clinical response to SIT. Asthma symptom score (ASS), rhinitis symptom score
(RSS),pulmonaryfunctionsandvisualanalogue scales (VAS)wereevaluated atthebeginningandafter2years. Results. There were
17boysand15girlswiththemeanageof10.78±3.03years.Themeanserumhousedustmites-IgElevelwas128.62±142.61kU/L,
t-IgE 608.90 ± 529.98IU/mL, and s-IgE/t-IgE ratio 33.83 ± 53.18. Before immunotherapy, ASS was 6.23 ± 1.63, RSS; 8.20 ± 1.88,
VAS; 7.38 ± 2.01, FEV1 (%); 89.14 ± 8.4 8 ,P E F( % ) ;8 8 .93 ± 13.57, and after 2 years, these values were determined as 1.90 ± 1.10,
3.05±1.39,1.35±1.24,97.6±11.26,and97.0±11.55,respectively.s-IgE/t-IgEratiowascorrelatedwithchangeinRSS(r =− 0.392,
P = 0.08) and VAS (r =− 0.367, P = 0.05). Conclusion. Although SIT is very eﬀective treatment, all patients do not beneﬁt from
treatment. We assumed that s-IgE/t-IgE ratio would be useful to predict the clinical response to SIT.
1.Introduction
Allergen-speciﬁc immunotherapy (SIT) has been used to
treat IgE-mediated rhinoconjunctivitis, asthma, and venom
hypersensitivity for almost a century. The clinical eﬃcacy
of SIT has been shown in several randomized, prospective,
double blind placebo-controlled studies [1–5]. A number of
studies have shown that SIT decreases clinical symptoms and
improves lung function and quality of life in allergicdiseases.
SIT is only curative and speciﬁc method of treatment and
may modify the natural course of the allergic disease [3–5].
Many complex immunologic changes occur during the
course of SIT. Immunological changes induced by SIT
are encompassing modulation of allergen-speciﬁc antibody
responses, reduction in recruitment and activation of proin-
ﬂammatory cells, and changes in the pattern of allergen-
speciﬁc T-cell responses [6–9]. It has been postulated that
regulatory T (Treg) cells can control an established allergic
response via distinct mechanisms. IL-10 and TGF-β decrease
IgE production and enhance IgG4 and IgA production,
respectively [1, 10–12]. Allergen-speciﬁc immunotherapy
frequently induced a transient initial increase in serum-
allergen speciﬁc IgE, and a subsequent decrease is observed
in the following months or years of SIT [13, 14]. Moreover,
successful SIT often elicits allergen-speciﬁc IgG4 and IgA
responses [6, 15–17]. However, a signiﬁcant decrease in the
allergen-speciﬁc IgE/IgG4 ratio occurs after several months.
Such changes in the IgE/IgG4 ratio have been found to
correlatewithadecreaseinthelate-phaseskinreactiontothe
allergen and with the overall clinical eﬃcacy of SIT in some
studies [16–19]. It is unclear how serum total IgE (t-IgE)
measurements, alone or in relation to s-IgE measurements,
or blood eosinophil (b-eos) counts should be interpreted, as2 Journal of Allergy
wellaswhatroletheyshouldplayinselectingpatientsforSIT
in clinical practice [20].
In this study, we aimed to evaluate whether speciﬁc IgE/
totalIgElevelscanpredictclinicalimprovementinmonosen-
sitized patients to house dust mite treated with immunother-
apy.
2. Patientsand Methods
We analyzed 32 children monosensitized to house dust mite
withthediagnosisofasthmaand/orallergicrhinitisthatwere
on followup in Cukurova University, Faculty of Medicine,
Division of Pediatric Allergy-Immunology, Adana, Turkey
between January 2007 and September 2010. All patients
underwent SIT by means of subcutaneous route as part of
the therapy.
All patients presented with a clinical diagnosis of asthma
and/or allergic rhinitis. Diagnosis of asthma and allergic
rhinitis was deﬁned according to GINA and ARIA criteria
[21, 22]. Skin prick tests, serum t-IgE and s-IgE levels, and
serum s-IgE/t-IgE ratios, asthma symptom scores (ASS),
rhinitis symptom scores (RSS), pulmonary functions, and
visual analogue scales (VAS) were evaluated at the beginning
and after 2 years in all patients.
Immunotherapy was administered by means of sub-
cutaneous route, and each patient received the maximum
tolerated dose, as per the manufacturer’s recommendations.
The maintenance dose was 0.8mL which corresponds to
3.84mg of the major allergens of D pteronyssinus and D
farinae.
Patients were divided into two groups according to the s-
IgE/t-IgE ratio. We set up 16.2 as a cut-oﬀ point for s-IgE/t-
IgEratio,andGroup1includedpatientswhohads-IgE/t-IgE
ratio <16.2, while Group 2 s-IgE/t-IgE ratio >16.2 [20].
2.1. SPT. A routine skin prick test was performed for all
patients using kits containing common inhalant allergens
(D. pteronyssinus, D. farinae, grass mix, tree mix, mold mix,
and Alternaria species) (ALK-Abello’, Madrid, Spain), and
an induration with a diameter of ≥3mm was accepted as a
positive reaction.
2.2. Total IgE. Total IgE levels were assayed by microparticle
enzyme immunoassay (Abott, USA).
2.3. spIgE. A blood sample was processed at the time of
diagnosis and after 2 years of SIT. s-IgE levels were deter-
mined by using the ﬂuoroimmunoassay technique (Unicap,
Phadia, Uppsala, Sweden) according to the manufacturer’s
instructions. Serum s-IgE levels were determined with a
detection limit of 0.35kAU/L. In all patients, the s-IgE level
was measured for the same allergens used in the skin prick
tests.
spIgE/t-IgE ratio was calculated as

spIgE/t −IgE

× 100. (1)
2.4. Asthma Symptom Score (ASS). Asthma symptom scores
were determined based on the daytime symptoms and
nocturnal awakening. In addition, the amount of as-needed
β2-agonist (salbutamol) was recorded daily as the number of
puﬀs. Daytime asthma symptoms and nocturnal awakenings
were scored subjectively, as follows: 0, no symptoms during
the day/night; 1, symptoms did not aﬀect daily activities or
nighttime sleep; 2, symptoms aﬀected at least 1 daily activity
ordisturbednighttimesleep;3,symptomsaﬀected2ormore
daily activities or disturbed sleep all night or most of the
night. Use of β2-agonists was scored as follows: 0, none; 1,
once a day; 2, between 2 and 3 times a day; 3, more than
3 times a day. The minimum score for each day was 0 (no
symptoms during the day, no symptoms at night, and no
use of β2-agonists), and the maximum score was 9 (severe
symptoms during the day and at night, and more than 3
administrations of β2-agonists) [23].
2.5. Rhinitis Symptom Score. Each nasal symptoms including
itching, congestion, sneezing, and rhinorrhea were scored
subjectively as follows: 0, no symptoms; 1, symptom positive
however did not aﬀect daily activities or nighttime sleep; 2,
symptoms were bothering but did not aﬀect daily activities
or nighttime sleep; 3, symptoms aﬀected daily activities or
disturbed sleep. Scores for each symptoms recorded and sum
of the scores were calculated (0–12) [24].
2.6. VAS (Visual Analogue Scale). Visual analogue scale was
evaluated on 10cm card [25].
2.7. Pulmonary Functions. PFTs were performed according
to the American Thoracic Society (ATS) Criteria by using
ZAN 100 Spiromed (Oberthulba, Germany), and the results
were expressed as percentages of the predicted values for age
and height [26].
2.8. Determination of Changes in Clinical Parameters. Chan-
ges in ASS, RSS, VAS, and pulmonary functions throughout
2 years were calculated by the following formula:
Change in ASS
=
ASS (before treatment) −ASS (after treatment)
ASS (before treatment)
×100.
(2)
Decreases in RSS, FEV1, PEF, and VAS were calculated with
same method.
2.9. Statistical Analysis. All statistical analysis was carried
out using a computer software (SPSS version 11.0; SPSS;
Chicago, Illinois, USA). Nonparametric Wilcoxon test was
utilized to compare the groups. Spearman’s correlation test
was used to determine the statistical relationships between
s-IgE/t-IgE ratio and changes in ASS, RSS, and VAS. The
P<0.05 value was considered as statistical signiﬁcant.Journal of Allergy 3
3. Results
3.1. The Characteristics of the Patients. There were 17 boys
and 15 girls with the mean age of 10.78 ± 3.03 years (range;
7–15 years). Sixteen patients had asthma, 4 patients had
allergicrhinitis,and12patientshadbothasthmaandallergic
rhinitis. At beginning of the immunotherapy, the mean total
IgE value was found to be 608.9 ± 529.987IU/mL, spIgE
and spIgE/t-IgE ratio were 128.62 ± 142.61kUA/L (median:
69.05) and 33.83 ± 53.18 (median: 17.68), respectively. The
characteristics of the patients were given in Table 1.
3.2. Changes in Clinical Symptoms, VAS, and Pulmonary
Functions. We found statistically signiﬁcant improvement in
asthma symptom score, rhinitis symptom score, pulmonary
functions, and VAS at the end of the 2 years of SIT (Table 2).
3.3. Correlation between the s-IgE/t-IgE Ratio and Changes
in ASS, RSS, Pulmonary Functions, and VAS. We analyzed
the correlations between the s-IgE/t-IgE ratio and changes
in ASS, RSS, pulmonary functions, and VAS in order to
determine whether this ratio would be useful to predict the
eﬃcacy of SIT. We found that s-IgE/t-IgE ratio was inversely
correlatedwiththechangeinRSSbutthiswasnotstatistically
signiﬁcant (r =− 0.392, P = 0.08). On the other hand,
signiﬁcant inverse correlation was determined between the
s-IgE/t-IgE ratio and change VAS (r =− 0.367, P = 0.05).
There was no signiﬁcant correlation between the s-IgE/t-IgE
ratioandchangesinASSandpulmonaryfunctions(Table3).
In addition, patients were divided into, two groups
according to the s-IgE/t-IgE ratio. Previously Di Lorenzo et
al. reported that serum s-IgE/t-IgE ratio of greater than 16.2
correlated with an eﬀective clinical response to SIT [20].
Based on this data, we set up 16.2 as a cut-oﬀ point for s-
IgE/t-IgE ratio [20]. Group 1 included patients who had s-
IgE/t-IgE ratio <16.2, while Group 2 included patients with
s-IgE/t-IgE ratio >16.2 (Table 4). According to this cut-oﬀ
point, we found signiﬁcant inverse correlation between the
s-IgE/t-IgE ratio and change in both RSS (r =− 0.432, P =
0.012) and VAS (r =− 0.483, P = 0.01). However, there
were no signiﬁcant correlations in Group 1 regarding these
parameters. In addition, no statistically signiﬁcant relation
was found between the s-IgE/t-IgE ratio and changes in ASS
and pulmonary functions in both groups.
4. Discussion
Allergen-speciﬁc immunotherapy has the potential to mod-
ify the natural course of allergic diseases [3–5, 27, 28].
Many diﬀerent in vivo and in vitro tests have been used
to determine the eﬃciency; however, predictive tests for the
clinical response to SIT are limited.
Successful immunotherapy is accompanied by the sup-
pression of numbers of T-helper 2 (Th2) eﬀector cells,
eosinophils, basophils, mast cells and neutrophils inﬁltration
in target organs, induction of IL-10 and/or TGF-β+T reg
cells, and increases in “protective” noninﬂammatory block-
ing antibodies, particularly IgG4 and IgA2 subclasses with
Table 1: The characteristics of the patients.
Characteristics
Age 10.78 ±3.03 (7–15 years)
Gender (F/M) 17/15
Diagnosis N (%)
Asthma 16/32 (50%)
Rhinitis 4/32 (12.5%)
Asthma and rhinitis 12/32 (37.5%)
Speciﬁc IgE (kuA/L) 128.62 ±142.61 (median: 69.05)
Total IgE 608.9 ±529.987
(Speciﬁc IgE/total IgE)×100 33.83 ±53.18 (median: 17.68)
Table 2: The changes in ASS, RSS, pulmonary functions, and VAS
following 2 years of SIT.
Parameters Before SIT After 2 years of SIT P value
ASS 6.23 ±1.63 1.90 ±1.10 0.000
RSS 8.20 ±1.88 3.05 ±1.39 0.000
FEV1 89.14 ±8.48 97.60 ±11.26 0.000
PEF 88.93 ±13.57 97.0 ±11.55 0.001
VAS 7.38 ±2.01 1.35 ±1.24 0.000
Table 3: Correlations between s-IgE/t-IgE ratio and change in ASS,
RSS, pulmonary functions, and VAS.
Correlations R value P value
ASS −0.115 0.54
RSS −0.392 0.08
FEV1 0.215 0.281
PEF 0.136 0.498
VAS −0.367 0.05
Table 4: Correlations between s-IgE/t-IgE ratio and change in ASS,
RSS, pulmonary functions and VAS based on cut oﬀ value 16.2 for
s-IgE/t-IgE ratio.
Correlations R value P value
GROUP 1 (s-IgE/t-IgE ≤16.2)
N = 16
ASS 0.239 0.410
RSS 0.116 0.780
FEV1 0.121 0.694
VAS 0.124 0.296
GROUP 2 (s-IgE/t-IgE >16.2)
N = 16
ASS −0.173 0.078
RSS −0.432 0.012
FEV1 0.249 0.091
VAS −0.483 0.01
inhibitory activity. This suppression occurs within weeks or
months as a consequence of the appearance of a population
of regulatory T cells that exert their eﬀects by mechanisms
involving cell-cellcontact,butalsobythereleaseofcytokines
such as IL-10 (increases IgG4) and TGF-β (increases speciﬁc4 Journal of Allergy
IgA). Mast cell and basophil desensitization are very early
eﬀects.Intermediateeﬀectsarerelatedtochangesinallergen-
speciﬁc T cells, and late aﬀects are related to B cells and
IgE as well as mast cells, basophils, and eosinophils [6].
Several successful immunotherapy studies have shown an
induction of peripheral tolerance and an anergic state in
activated speciﬁc T cells [10–12, 27, 28]. On the other
hand, a signiﬁcant decrease in skin prick test reactivity
can be also observed relatively late in the course [3–5].
Therefore, many clinicians want to ﬁnd out objective and
easily performed parameters to predict the eﬃcacy of SIT.
Recently, Di Lorenzo et al. demonstrated that the calculation
of the serum s-IgE/t-IgE ratio could be useful for predicting
the clinical response to SIT oﬀering an advantage over
measuring t-IgE and s-IgE levels in monosensitized patients
for the following allergens: grass, Parietaria judaica [20]. To
support this idea, in this study, we evaluate whether s-IgE/t-
IgEratiocanpredictclinicalimprovementinmonosensitized
patients to house dust mite treated with immunotherapy
and found that s-IgE/t-IgE ratio would be useful to predict
the clinical response to SIT especially in patients with
allergic rhinitis. In our study, we demonstrated statistically
signiﬁcant correlation between the s-IgE/t-IgE ratio and
change in VAS and RSS. Visual analogue scores and rhinitis
symptom scores improved in children with s-IgE/t-IgE ratio
higher than 16.2 at the end of the 2 years of SIT.
The continuous hyperreactivity in skin prick test might
have negative impact on motivation of both physicians
and patients. Therefore, diﬀerent objective and practical
parameters are needed to evaluate the clinical response to
SIT. Nasal and/or bronchial provocation tests, diluted skin
prick tests, SpIG4 levels, or other detailed tests are usually
used in clinical studies or studies aimed to investigate the
eﬀectiveness of SIT. However, it is generally diﬃcult to
perform all these tests in routine practice because of ethical
and economic issues. In this study, we evaluate whether this
simple s-IgE/t-IgE ratio can predict clinical improvement in
such patients routinely and we assumed that this ratio would
be helpful to predict the eﬃcacy of SIT in clinical practice.
Allergen-speciﬁc immunotherapy is of long-duration
therapy, and at least 3–5-year treatment was recommended
for the best clinical beneﬁts [29, 30]. Because not all patients
beneﬁt from treatment, it is important to be able to have
speciﬁc criteria to determine those patients who might best
beneﬁt from this therapy and decide when to discontinue
SIT. We found that the serum s-IgE/t-IgE ratio would be
a good predictor of clinical response to allergen-speciﬁc
immunotherapy and this ratio might be useful for deciding
whentodiscontinuetheSITaswell.Howeverfurther,studies
in larger series are needed.
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